SCOPUS 정보 검색 플랫폼

Volumn 4, Issue 1, 2010, Pages 16-18

Editorial: The potential successes and challenges of targeted anticancer therapies

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL FACTOR;

DRUG ANTAGONISM; DRUG DESIGN; EDITORIAL; HUMAN; NEOPLASM;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL FACTORS; DRUG DESIGN; HUMANS; NEOPLASMS;

EID: 77950364128 PISSN: 17514258 EISSN: 17514266 Source Type: Journal
DOI: 10.1097/SPC.0b013e3283357619 Document Type: Editorial

Times cited : (4)

References (8)

1
- 0036186028
- New molecular targets of breast cancer therapy
- Sauer G, Deissler H, Kurzeder C, Kreienberg R. New molecular targets of breast cancer therapy. Strahlenther Onkol 2002; 178:123-133.
- (2002) Strahlenther Onkol , vol.178 , pp. 123-133
- Sauer, G.¹ Deissler, H.² Kurzeder, C.³ Kreienberg, R.⁴

2
- 70350571201
- Metastatic renal cell carcinoma: Recent advances in the targeted therapy era
- Di Lorenzo G, Autorino R, Sternberg CN. Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 2009; 56:959-973.
- (2009) Eur Urol , vol.56 , pp. 959-973
- Di Lorenzo, G.¹ Autorino, R.² Sternberg, C.N.³

3
- 0018044997
- Biochemical programs and enzymepattern-targeted chemotherapy in cancer cells
- Weber G, Olah E, Lui MS, Tzeng D. Biochemical programs and enzymepattern-targeted chemotherapy in cancer cells. Adv Enzyme Regul 1978; 17:1-21.
- (1978) Adv Enzyme Regul , vol.17 , pp. 1-21
- Weber, G.¹ Olah, E.² Lui, M.S.³ Tzeng, D.⁴

4
- 0035122485
- Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase
- Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001; 7:228-234.
- (2001) Nat Med , vol.7 , pp. 228-234
- Vigneri, P.¹ Wang, J.Y.²

5
- 70350772288
- Tyrosine kinase inhibitors: A review on pharmacology, metabolism and side effects
- Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors: a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009; 10:470-481.
- (2009) Curr Drug Metab , vol.10 , pp. 470-481
- Hartmann, J.T.¹ Haap, M.² Kopp, H.G.³ Lipp, H.P.⁴

6
- 27244452464
- High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
- Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23:7013-7023.
- (2005) J Clin Oncol , vol.23 , pp. 7013-7023
- Romaguera, J.E.¹ Fayad, L.² Rodriguez, M.A.³

7
- 49249113484
- Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
- Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26:3709-3714.
- (2008) J Clin Oncol , vol.26 , pp. 3709-3714
- Azad, N.S.¹ Posadas, E.M.² Kwitkowski, V.E.³

8
- 34548222618
- Lapatinib-associated toxicity and practical management recommendations
- Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007; 12:756-765.
- (2007) Oncologist , vol.12 , pp. 756-765
- Moy, B.¹ Goss, P.E.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.